Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis

Yui Kanazawa, Yuka Yamashita, Mitsuhiro Fujiwara, Michiko Muraoka, Kana Washio, Kiichiro Kanamitsu, Hisashi Ishida, Takae Nakano, Miho Yamada, Keizo Horibe, Takehiro Tanaka, Tadashi Yoshino, Akira Shimada

Research output: Contribution to journalArticle

Abstract

Childhood anaplastic large cell lymphoma (ALCL) accounts for approx. 10-30% of cases of non-Hodgkin lymphoma, and the ALCL99 study reported 60-75 disease-free survival; however, a relatively high relapse rate was observed (25-30% ). We report 2 patients with Stage III ALCL who relapsed 6-18 months after the end of ALCL99 chemotherapy. A retrospective molecular analysis identified the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) fusion gene in the first diagnostic bone marrow samples taken from both patients. However, antibodies against the ALK protein appeared to be relatively low in the serum of both patients (×100 and ×750). An increase in chemotherapy intensity may be beneficial if Stage III ALCL patients are shown to be NPM-ALK chimera-positive in the first diagnostic bone marrow sample.

Original languageEnglish
Pages (from-to)503-506
Number of pages4
JournalActa Medica Okayama
Volume70
Issue number6
Publication statusPublished - Dec 1 2016

Fingerprint

Anaplastic Large-Cell Lymphoma
Bone
Chemotherapy
Fusion reactions
Bone Marrow
Drug Therapy
Gene Fusion
Genes
Non-Hodgkin's Lymphoma
Disease-Free Survival
Antibodies
Recurrence
nucleophosmin
anaplastic lymphoma kinase
Proteins
Serum

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis. / Kanazawa, Yui; Yamashita, Yuka; Fujiwara, Mitsuhiro; Muraoka, Michiko; Washio, Kana; Kanamitsu, Kiichiro; Ishida, Hisashi; Nakano, Takae; Yamada, Miho; Horibe, Keizo; Tanaka, Takehiro; Yoshino, Tadashi; Shimada, Akira.

In: Acta Medica Okayama, Vol. 70, No. 6, 01.12.2016, p. 503-506.

Research output: Contribution to journalArticle

Kanazawa, Y, Yamashita, Y, Fujiwara, M, Muraoka, M, Washio, K, Kanamitsu, K, Ishida, H, Nakano, T, Yamada, M, Horibe, K, Tanaka, T, Yoshino, T & Shimada, A 2016, 'Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis', Acta Medica Okayama, vol. 70, no. 6, pp. 503-506.
Kanazawa, Yui ; Yamashita, Yuka ; Fujiwara, Mitsuhiro ; Muraoka, Michiko ; Washio, Kana ; Kanamitsu, Kiichiro ; Ishida, Hisashi ; Nakano, Takae ; Yamada, Miho ; Horibe, Keizo ; Tanaka, Takehiro ; Yoshino, Tadashi ; Shimada, Akira. / Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis. In: Acta Medica Okayama. 2016 ; Vol. 70, No. 6. pp. 503-506.
@article{deadaae3cab94121a5d2e74366691859,
title = "Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis",
abstract = "Childhood anaplastic large cell lymphoma (ALCL) accounts for approx. 10-30{\%} of cases of non-Hodgkin lymphoma, and the ALCL99 study reported 60-75 disease-free survival; however, a relatively high relapse rate was observed (25-30{\%} ). We report 2 patients with Stage III ALCL who relapsed 6-18 months after the end of ALCL99 chemotherapy. A retrospective molecular analysis identified the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) fusion gene in the first diagnostic bone marrow samples taken from both patients. However, antibodies against the ALK protein appeared to be relatively low in the serum of both patients (×100 and ×750). An increase in chemotherapy intensity may be beneficial if Stage III ALCL patients are shown to be NPM-ALK chimera-positive in the first diagnostic bone marrow sample.",
author = "Yui Kanazawa and Yuka Yamashita and Mitsuhiro Fujiwara and Michiko Muraoka and Kana Washio and Kiichiro Kanamitsu and Hisashi Ishida and Takae Nakano and Miho Yamada and Keizo Horibe and Takehiro Tanaka and Tadashi Yoshino and Akira Shimada",
year = "2016",
month = "12",
day = "1",
language = "English",
volume = "70",
pages = "503--506",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "6",

}

TY - JOUR

T1 - Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis

AU - Kanazawa, Yui

AU - Yamashita, Yuka

AU - Fujiwara, Mitsuhiro

AU - Muraoka, Michiko

AU - Washio, Kana

AU - Kanamitsu, Kiichiro

AU - Ishida, Hisashi

AU - Nakano, Takae

AU - Yamada, Miho

AU - Horibe, Keizo

AU - Tanaka, Takehiro

AU - Yoshino, Tadashi

AU - Shimada, Akira

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Childhood anaplastic large cell lymphoma (ALCL) accounts for approx. 10-30% of cases of non-Hodgkin lymphoma, and the ALCL99 study reported 60-75 disease-free survival; however, a relatively high relapse rate was observed (25-30% ). We report 2 patients with Stage III ALCL who relapsed 6-18 months after the end of ALCL99 chemotherapy. A retrospective molecular analysis identified the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) fusion gene in the first diagnostic bone marrow samples taken from both patients. However, antibodies against the ALK protein appeared to be relatively low in the serum of both patients (×100 and ×750). An increase in chemotherapy intensity may be beneficial if Stage III ALCL patients are shown to be NPM-ALK chimera-positive in the first diagnostic bone marrow sample.

AB - Childhood anaplastic large cell lymphoma (ALCL) accounts for approx. 10-30% of cases of non-Hodgkin lymphoma, and the ALCL99 study reported 60-75 disease-free survival; however, a relatively high relapse rate was observed (25-30% ). We report 2 patients with Stage III ALCL who relapsed 6-18 months after the end of ALCL99 chemotherapy. A retrospective molecular analysis identified the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) fusion gene in the first diagnostic bone marrow samples taken from both patients. However, antibodies against the ALK protein appeared to be relatively low in the serum of both patients (×100 and ×750). An increase in chemotherapy intensity may be beneficial if Stage III ALCL patients are shown to be NPM-ALK chimera-positive in the first diagnostic bone marrow sample.

UR - http://www.scopus.com/inward/record.url?scp=85013848085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013848085&partnerID=8YFLogxK

M3 - Article

VL - 70

SP - 503

EP - 506

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 6

ER -